Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis

The Journal of Investigative Dermatology
Lothar F FeckerJürgen Eberle

Abstract

Prognosis of primary melanoma is presently based on morphological parameters, mainly tumor thickness. However, more reliable prognostic markers are needed that allow a better stratification of patients, especially with regard to therapeutic options. Here, a retrospective study was performed on patients with primary superficial-spreading melanoma (SSM, n=44) or nodular melanoma (n=16) of 1.5-4 mm thickness. Thirty patients had survived the follow-up of 10 years, whereas the other 30 patients developed metastases. Tumor sections were analyzed by immunohistochemistry for the expression of regulators of the cell cycle (p21; retinoblastoma protein (pRb)), of the intrinsic or extrinsic proapoptotic pathways (p53; murine double minute gene 2 protein; tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-R1/DR4; TRAIL-R2/DR5) and of Bcl-2-related proteins (Bcl-2, Mcl-1, Bax, Bak, Bok), which regulate the common mitochondrial apoptotic pathway. In SSM, decrease of Bax and Bak was significantly correlated with a poor prognosis: high Bax was associated with 10-year survival rates of 68%, whereas low Bax resulted in only 26% survival, and high Bak was associated with 10-year survival rates of 62%, whereas low Bak resulted in onl...Continue Reading

References

Nov 14, 1997·Proceedings of the National Academy of Sciences of the United States of America·S Y HsuA J Hsueh
Mar 17, 2001·Journal of Clinical Pathology·J GeorgievaD Schadendorf
Aug 21, 2001·The Journal of Investigative Dermatology·M RaisovaC C Geilen
Oct 5, 2001·Skin Pharmacology and Applied Skin Physiology·C Garbe, A Blum
Apr 19, 2002·Biochimica Et Biophysica Acta·Karen H Vousden
Jul 11, 2002·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·M KorabiowskaU Brinck
Sep 5, 2002·Nature Reviews. Cancer·Suzanne Cory, Jerry M Adams
Dec 13, 2002·International Journal of Cancer. Journal International Du Cancer·Dilek GünerPeter T Daniel
Jun 6, 2003·The Journal of Investigative Dermatology·Christiane ThallingerBurkhard Jansen
Jun 6, 2003·Oncogene·María S Soengas, Scott W Lowe
Oct 31, 2003·Essays in Biochemistry·Peter T DanielDilek Güner
Mar 5, 2004·Biochimica Et Biophysica Acta·Martin R Sprick, Henning Walczak
Apr 23, 2004·The Journal of Biological Chemistry·Alexander G YakovlevAlan I Faden
Oct 30, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas K EigentlerUNKNOWN Central Malignant Melanoma Registry of the German Dermatological Society
Nov 18, 2004·International Journal of Oncology·Ingeborg M BachmannLars A Akslen
Jan 19, 2005·The Journal of Investigative Dermatology·Lothar F FeckerJürgen Eberle
Apr 2, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Soheil S DadrasMichael Detmar

❮ Previous
Next ❯

Citations

Jan 16, 2007·Archives of Dermatological Research·Jochen UtikalSelma Ugurel
Dec 20, 2008·Clinics in Dermatology·J Andrew CarlsonAndrze J Slominski
May 17, 2006·The Journal of Investigative Dermatology·Martin Leverkus, Harald Gollnick
Nov 29, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·René HandrickVerena Jendrossek
Jun 18, 2010·The Journal of Investigative Dermatology·Bonnie E Gould Rothberg, David L Rimm
Dec 7, 2007·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jürgen EberleLothar F Fecker
Oct 2, 2007·Dermatologic Clinics·Emmanuel ContassotLars E French
May 25, 2012·Expert Opinion on Therapeutic Targets·Helena PópuloJosé Manuel Lopes
Mar 22, 2007·Expert Opinion on Therapeutic Targets·Georg Häcker, Stefan A Paschen
Mar 15, 2015·Surgical Oncology Clinics of North America·Edmund K Bartlett, Giorgos C Karakousis
Jun 4, 2010·Anais Brasileiros De Dermatologia·Georgi Tchernev, Pietro Nenoff
Mar 29, 2014·Experimental Dermatology·Michael Plötz, Jürgen Eberle
Jul 13, 2013·Wiener medizinische Wochenschrift·Kristina SemkovaUwe Wollina
Oct 23, 2010·Expert Review of Molecular Diagnostics·Monica NeaguCristiana Tanase
Jun 27, 2009·Cancer Control : Journal of the Moffitt Cancer Center·Selma UgurelJürgen C Becker
Dec 17, 2010·Experimental Dermatology·Caterina LongoLance A Liotta
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jonathan Begley, Antoni Ribas
Jun 24, 2011·Cancer Research·Cláudia Trindade NunesStephen Man

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis